English region where men use most Viagra revealed – where does your town rank?
STIFF COMPETITION English region where men use most Viagra revealed – where does your town rank?
Click to share on X/Twitter (Opens in new window)
Click to share on Facebook (Opens in new window)
FELLAS from Yorkshire need most help rising to the occasion in the bedroom, according to new figures.
Chaps in the county are given the most prescriptions for Viagra or similar drugs to aid performance.
Sign up for Scottish Sun
newsletter
Sign up
2
NHS stats show men in the North used the little blue pills much more often than in the South last year.
The East Riding of Yorkshire, including the towns of Goole, Beverley and Bridlington, topped the table with 3.572 per cent needing them.
But it faced stiff opposition from Northumberland with 3.359 per cent.
Other Yorkshire towns where a high proportion of men needed a bedtime boost were Rotherham, Barnsley and Scarborough.
Meanwhile, those in Dorset, including the coastal towns of Poole and Bournemouth which are popular with retired folk, also made the top five with 3.274 per cent.
But fellas in large areas of London, Cambridgeshire and Berkshire were far less likely to get the prescription.
Leicester had the lowest rate at 1.5 per cent.
Consultant urologist Gordon Muir, of London Bridge Hospital, said: 'NHS provision of this treatment can vary from region to region, as can the ratio of underlying disease which probably explains some of the differences.'
Inside UK's fake Viagra epidemic…agonising three-day effects, 50p hits and deadly drugs, drywall & ink used as 'fillers'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
6 minutes ago
- Times
Obese to get soups and shakes diet instead of weight-loss jabs
Low-calorie soups and shakes are to be prescribed to thousands of overweight people in Scotland in an attempt to reduce their dependence on expensive weight-loss drugs and provide longer-lasting health benefits. From January, 3,000 patients who have been newly diagnosed with type 2 diabetes will be recruited for a clinical trial. About 300,000 Scots live with type 2 diabetes, a condition commonly linked to obesity, in which badly regulated blood sugar levels can increase the risk of heart disease, kidney disease, strokes or nerve conditions. About 10,000 of them are being treated with weight-loss drugs such as Ozempic, Wegovy and Mounjaro, with injections costing the NHS £3,000 a year. The estimated annual bill of £30 million is expected to rise as manufacturers raise prices. NHS chiefs believe that not only will the soups and shakes plan be less expensive, it will also bring longer-term health benefits. In the Total Diet Replacement (TDR) plan, to be rolled out over three years, patients who have recently been diagnosed with type 2 diabetes and are deemed eligible will be given low-calorie substitutes for their breakfast, lunch and dinner. The replacement meals, containing a maximum of 900 calories a day, will be delivered to patients for between three and five months. • What to do now Mounjaro's hiking its prices, by an obesity expert After this initial period, normal food will be reintroduced, but with guidance given on healthy meals through online consultations and an app. The ambition is for patients to lose up to 10 per cent of their body weight over a year. Doctors are also optimistic that up to 40 per cent of the trial participants will achieve remission from type 2 diabetes within a year. There are fears that the weight lost through injections — which work by suppressing the appetite — may last only as long as the patient is taking the drug. By contrast, the effects of diet changes should prove more long-lasting and cost effective, NHS officials believe. The TDR scheme is set to cost £5.6 million for 3,000 patients, a one-off cost of about £1,866 per person. Doctors hope the plan will help patients to fundamentally alter their diet and lifestyle. A spokesman for the Scottish government said: 'We anticipate that around 35 to 40 per cent will achieve remission from type 2 diabetes at the end of their first year on the programme, with a majority of patients benefiting from a clinically significant average weight loss of 10 per cent.' This would lead to reductions in blood pressure and contribute to a reduced risk of cardiovascular disease. He added: 'We will measure impact by the number of patients recruited into this programme, the number who achieve remission and the number with clinically significant weight loss.'
Economist
3 hours ago
- Economist
Why America can't shake off inflation
The Yiddish phrase 'farshlepteh krenk', untranslatable into English, describes an illness that just won't go away. That is how some rich countries' experience of inflation has felt. The rate of price increases has fallen sharply since the acute phase in 2022, when inflation across the OECD rose to nearly 11%, its highest since the 1970s. In June average inflation across the club was around 2.5%, only a smidge above most central banks' targets. But many Anglophone countries still have lingering symptoms.
The Independent
3 hours ago
- The Independent
Pricing people out of using Mounjaro would be bad news for the NHS
There were scenes of shock in pharmacies across the country when a notice from pharmaceutical giant Eli Lilly hit inboxes out of nowhere last week. The wholesale price of their popular weight-loss drug Mounjaro, administered via jabs, was going to more than double from the start of September. While Eli Lilly has struck an, as yet secret, deal with the NHS, this massive increase will hit the vast majority of patients who are prescribed Mounjaro privately. More than a million Britons are estimated to already be taking Mounjaro, and scores more are interested in using it to start their weight-loss journey. So, when the news of this massive price hike went public, it wasn't only pharmacists who were worried and disappointed. The first message to concerned patients is don't panic and don't stop taking your medication; your local pharmacy is ready and willing to talk you through the options going forward. There are alternatives to Mounjaro that, for now at least, remain cheaper. They may be right for you, but it is essential that you get professional advice before you do anything, and your neighbourhood pharmacist is best placed and most on hand to give that advice. The consequences of this unprecedented price hike won't just hit patients; they will also hit the pharmacies on Britain's high streets. The finances of the whole pharmacy sector are already in a state of crisis after years of underfunding. The price hike for Mounjaro will put it under more financial strain. Unless the government steps in and offers the sector a fairer funding settlement for our NHS work, then, inevitably, we are going to see more pharmacies close and more communities robbed of the vital service on their street corner. If the government really wants pharmacies to be the 'front door' of their Neighbourhood Health Service, then it needs to act now. We call on the other weight-loss manufacturers to hold their nerve and hold their prices. The British market for weight-loss jabs was only set to grow, but it will only achieve that growth if treatment remains affordable to the average patient. There is a real danger that patients priced out of Mounjaro, but anxious to maintain treatment, turn to sourcing replacements online. If other manufacturers follow suit and up their prices, that danger will only grow. In their desperation, patients could well end up sourcing counterfeit jabs online, which are completely unregulated and potentially extremely harmful. At the click of a mouse, patients can find themselves buying jabs that they have no idea what they contain, or if they were manufactured in safe conditions, no matter what picture the unscrupulous sites use to tempt them in. We are urging patients to be extremely cautious and vigilant when looking to buy weight loss medication online. If it looks too good to be true, it almost certainly is. Again, talk to your trained and regulated community pharmacy, which is there to help. There is a real risk it won't end here. Although the companies would deny it, tariffs and the noise from the White House would seem to be hitting this side of the Atlantic. British patients must not become pawns in a wider dispute about the costs of medicines arising from President Trump's recent letter to the US drug manufacturers. For now, it seems that weight-loss jabs prescribed privately are the easy win for the pharma giants, but we are concerned that more companies may increase the prices of more medicines as a result of tariffs. Any increases in wholesale prices, even for those drugs prescribed by the NHS, will impact the sustainability of the sector. The Mounjaro price hike came out of the blue. It could prove just the start. Exploding prices for pharmaceuticals risks a genuine and rapid crisis. Ministers need to urgently develop contingency plans; otherwise, we risk the system that keeps vital medicines flowing to patients entering an unprecedented era of uncertainty.
